You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
苑東生物(688513.SH):伊班膦酸鈉注射液國內首家通過一致性評價
格隆匯 03-30 17:24

格隆匯3月30日丨苑東生物(688513.SH)宣佈,公司於近日收到國家藥監局核准簽發的化學藥品“伊班膦酸鈉注射液”的《藥品補充申請批准通知書》。

該品種用於治療絕經後骨質疏鬆症、治療惡性腫瘤溶骨性骨轉移引起的骨痛、預防乳腺癌骨轉移患者骨相關事件的發生(包括病理性骨折、需放療或手術的骨併發症)以及治療伴有或不伴有骨轉移的惡性腫瘤引起的高鈣血癥。

截止公吿日,公司在該產品一致性評價項目上已投入研發費用約1116.09萬元。2020年公司的伊班膦酸鈉注射液銷售收入約為1.94億元。

公司表示,公司伊班膦酸鈉注射液國內首家通過一致性評價,有利於提高該產品的市場競爭力,對公司未來的經營業績產生積極的影響,同時為公司後續一致性評價產品研究工作積累了寶貴經驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account